Exploratory data base study: TEMPO post-hoc AI based image analysis study

Exploratory data base study: TEMPO post-hoc AI based image analysis study - TEMPO image AI study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047533

Enrollment

1444

Registered

2022-04-21

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who are participated in tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Exclusion criteria

Exclusion criteria: Same as Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Design outcomes

Primary

Measure	Time frame
Tolvaptan's renal protective effect (Categorized evaluation of kidney function through the change) Kidney function progression in placebo group (categorized evaluation of worsening renal function in the placebo group)	—

Countries

Japan,North America,South America,Australia,Europe

Contacts

Public ContactToshiki Tanaka

Otsuka Pharmaceutical Ltd. Medical Affairs

Tanaka.toshiki@otsuka.jp03-6717-1400

Outcome results